False-negative rate in the extended prospective TATTOO trial evaluating targeted axillary dissection by carbon tattooing in clinically node-positive breast cancer patients receiving neoadjuvant systemic therapy
Jana de Boniface(Harvard University), Steffi Hartmann(University of Rostock), Jan Frisell(Karolinska University Hospital), Toralf Reimer(University of Rostock), Per Olof Nyman(Skaraborg Hospital), Ingrid Wiklander-Bråkenhielm(Saint Göran Hospital), Athanasios Zouzos(Karolinska University Hospital), Karin Dembrower(Karolinska Institutet), Bernd Gerber(Universitäts Frauenklinik), Thorsten Kühn(Klinikum Esslingen)
Cited by 31
Related Papers
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
|The Lancet|2014|4.7k
Artificial intelligence for breast cancer detection in screening mammography in Sweden: a prospective, population-based, paired-reader, non-inferiority study
|The Lancet Digital Health|2023|316
External Evaluation of 3 Commercial Artificial Intelligence Algorithms for Independent Assessment of Screening Mammograms
|JAMA Oncology|2020|284